<?xml version="1.0" encoding="UTF-8"?>
<p>In addition, several pharmacologically active structural units, for example, pyridazines, 1,2,4-triazines and 1,2,3-triazoles are being explored to identify novel lead antimicrobial molecules (
 <xref ref-type="fig" rid="F0003">Figure 3</xref>). The pyridazine derivative 
 <bold>IX</bold> revealed promising 
 <italic>in vitro</italic> antimicrobial activities against Gram + ve and Gram -ve bacteria in comparison with tetracycline
 <xref rid="CIT0028" ref-type="bibr">
  <sup>28</sup>
 </xref>. Nagawade 
 <italic>et al.</italic> reported that the pyridazine-3-carboxylic acid analogue 
 <bold>X</bold> showed gratifying 
 <italic>in vitro</italic> antibacterial results approaching that of corresponding reference, ciprofloxacin
 <xref rid="CIT0029" ref-type="bibr">
  <sup>29</sup>
 </xref>. Compound containing 1,2,4-triazine nucleus 
 <bold>XI</bold> has been reported to possess better antimicrobial activity with less toxicity than ciprofloxacin
 <xref rid="CIT0030" ref-type="bibr">
  <sup>30</sup>
 </xref>. The derivative bearing 1,2,3-triazole scaffold 
 <bold>XIIa</bold> displayed overall encouraging efficiency against all screened microbial strains except 
 <italic>Aspergillus niger</italic>, while the other derivative 
 <bold>XIIb</bold> exhibited better antimicrobial potency against all strains except 
 <italic>Bacillus subtilis</italic> and 
 <italic>Aspergillus niger</italic>
 <xref rid="CIT0031" ref-type="bibr">
  <sup>31</sup>
 </xref>.
</p>
